Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LYN | P07948 | 17/20 | 0.58 |
| ▸ | KDR | P35968 | 17/20 | 0.58 |
| ▸ | LCK | P06239 | 16/20 | 0.58 |
| ▸ | SRC | P12931 | 16/20 | 0.58 |
| ▸ | INSR | P06213 | 14/20 | 0.58 |
| ▸ | HCK | P08631 | 14/20 | 0.58 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1827464 | 0.93 | LCK (0.69) | LYNKDRLCKSRCINSR | |
| SCHEMBL13269702 | 0.91 | LCK (0.61) | LYNKDRLCKSRCINSR | |
| SCHEMBL13269782 | 0.91 | LYN (0.56) | LYNKDRLCKSRCINSR | |
| SCHEMBL3232951 | 0.90 | LCK (0.56) | LYNKDRLCKSRCINSR | |
| SCHEMBL3238280 | 0.90 | BRAF (0.57) | LYNKDRLCKSRCINSR | |
| SCHEMBL3241487 | 0.89 | LCK (0.74) | LYNKDRLCKSRCINSR | |
| SCHEMBL3232981 | 0.89 | LYN (0.54) | LYNKDRLCKSRCINSR | |
| SCHEMBL13291962 | 0.88 | LYN (0.52) | LYNKDRLCKSRCINSR | |
| SCHEMBL1829414 | 0.88 | LCK (0.49) | LYNKDRLCKSRCINSR | |
| SCHEMBL13467360 | 0.88 | LYN (0.54) | LYNKDRLCKSRCINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758892-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-10-17 | — | — | EP | claimed |
| JP-4688876-B2 | — | — | 2011-05-25 | — | — | JP | claimed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | claimed |
| US-20070225286-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-27 | — | — | US | claimed |
| EP-1758892-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-03-07 | — | — | EP | claimed |
| WO-2005123719-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-12-29 | — | — | WO | claimed |
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| WO-2014172616-A2 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-23 | — | — | WO | disclosed |
| EP-1758892-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-10-17 | — | — | EP | disclosed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | disclosed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | disclosed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | disclosed |
| US-20070225286-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SOD1, NEFM | LYN 4794/4885KDR 4431/4885LCK 4772/4885 |
| US-20070225286-A1 | Compounds and Compositions as Protein Kinase Inhibitors | BMX, PTK2B, SRC | LYN 81/4885KDR 311/4885LCK 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.